Base de dados : LILACS
Pesquisa : D03.383.742.686.850.877.500 [Categoria DeCS]
Referências encontradas : 18 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 18 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887222
Autor: Rezaee-Zavareh, Mohammad Saeid; Hesamizadeh, Khashayar; Behnava, Bita; Alavian, Seyed Moayed; Gholami-Fesharaki, Mohammad; Sharafi, Heidar.
Título: Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis
Fonte: Ann. hepatol;16(2):188-197, Mar.-Apr. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background and aim. The combination of Sofosbuvir (SOF) and Ledipasvir (LDV) has been lead to considerable enhancement of treatment of hepatitis C virus (HCV) genotype 1 infection. A meta-analysis of the currently available studies was undertaken with the aim to evaluate the antiviral efficacy of SOF/LDV therapy for 12 or 24 weeks with or without Ribavirin (RBV) in patients with HCV genotype 1 infection. Material and methods. In this meta-analysis, we searched databases including PubMed, Scopus, Science Direct and Web of Science using appropriate keywords. All papers which evaluated the efficacy of combination therapy of SOF/LDV with or without RBV for 12 or 24 weeks among patients with HCV genotype 1 infection were included. Results. The 20 published articles were assessed for eligibility and finally 10 articles pooling 2248 participants were included in this meta-analysis. Pooled SVR12 for four SOF/LDV regimens were 95% (95%CI = 93%-97%) for 12 weeks of treatment with SOF/LDV, 97% (95%CI = 95%-98%) for 24 weeks of treatment with SOF/LDV, 96% (95%CI = 94%-97%) for 12 weeks of treatment with SOF/ LDV/RBV and 98% (95%CI = 97%-99%) for 24 weeks of treatment with SOF/LDV/RBV. Only in treatment regimen of SOF/LDV for 12 weeks, cirrhosis had a significant effect on the SVR12 (OR = 0.21, 95%CI = 0.07-0.66). Furthermore, NS5A resistance-associated substitutions at baseline were associated with decrease in the rate of SVR (OR = 0.31, 95%CI = 0.2-0.5). Conclusions. The Interferon-free regimen of SOF/LDV for 12 or 24 weeks with or without RBV is highly effective for treatment of patients with HCV genotype 1 infection.
Descritores: Antivirais/uso terapêutico
Benzimidazóis/uso terapêutico
Hepatite C/tratamento farmacológico
Hepacivirus/efeitos dos fármacos
Fluorenos/uso terapêutico
Sofosbuvir/uso terapêutico
-Antivirais/efeitos adversos
Ribavirina/uso terapêutico
Fatores de Tempo
Benzimidazóis/efeitos adversos
Distribuição de Qui-Quadrado
Razão de Chances
Resultado do Tratamento
Hepatite C/diagnóstico
Hepatite C/virologia
Hepacivirus/genética
Quimioterapia Combinada
Fluorenos/efeitos adversos
Sofosbuvir/efeitos adversos
Resposta Viral Sustentada
Genótipo
Limites: Humanos
Responsável: BR1.1 - BIREME


  2 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-887241
Autor: Vinaixa, Carmen; Berenguer, Marina.
Título: Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir/Sofosbuvir Plus Ribavirin Pretransplant
Fonte: Ann. hepatol;16(3):322-323, May.-Jun. 2017.
Idioma: en.
Projeto: Instituto de Salud Carlos III.
Descritores: Hepatite C
Hepacivirus
-Ribavirina
Benzimidazóis
Fluorenos
Sofosbuvir
Limites: Humanos
Responsável: BR1.1 - BIREME


  3 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-887248
Autor: Langness, Jacob A; Tabano, David; Wieland, Amanda; Tise, Sarah; Pratt, Lindsay; Harrington, Lauren Ayres; Lin, Sonia; Ghuschcyan, Vahram; Nair, Kavita V; Everson, Gregory T.
Título: Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy
Fonte: Ann. hepatol;16(3):366-374, May.-Jun. 2017. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction. Interferon-free, multi-direct acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection is highly effective and well tolerated, but costly. To gain perspective on the evolving economics of HCV therapy, we compared the cost per cure of a multi-DAA regimen with the prior standard of triple therapy. Material and methods. Patients infected with HCV genotype 1 who were treated through the University of Colorado Hepatology Clinic between May 2011 and December 2014 comprised the study population. The multi-DAA regimen of simeprevir plus sofosbuvir (SMV/SOF) was compared to the triple therapy regimen consisting of peginterferon and ribavirin, with either boceprevir or telaprevir (TT). Sustained-virologic response (SVR) rates, total costs per treatment and adverse events were recorded. Total cost per SVR were compared for the two treatments, controlling for patient demographics and clinical characteristics. Results. One hundred eighty-three patients received SMV/SOF (n = 70) or TT (n = 113). Patients receiving SMV/SOF were older, more treatment experienced, and had a higher stage of fibrosis. SVRs were 86% and 59%, average total costs per patient were $152,775 and $95,943, and average total costs per SVR were $178,237 vs. $161,813.49 for SMV/SOF and TT groups, respectively. Medication costs accounted for 98% of SMV/SOF and 85% of TT treatment costs. Conclusion. The high cure rate of multi-DAA treatment of HCV is offset by the high costs of the DAAs, such that the cost per cure from TT to multi-DAA therapy has been relatively constant. In order to cure more patients, either additional financial resources will need to be allocated to the treatment of HCV or drug costs will need to be reduced.
Descritores: Inibidores de Proteases/economia
Inibidores de Proteases/uso terapêutico
Hepacivirus/efeitos dos fármacos
Hepatite C Crônica/economia
Hepatite C Crônica/tratamento farmacológico
Simeprevir/economia
Simeprevir/uso terapêutico
Sofosbuvir/economia
Sofosbuvir/uso terapêutico
-Ambulatório Hospitalar/economia
Inibidores de Proteases/efeitos adversos
Indução de Remissão
Colorado
Resultado do Tratamento
Análise Custo-Benefício
Hepacivirus/enzimologia
Hepacivirus/genética
Modelos Econômicos
Hepatite C Crônica/diagnóstico
Hepatite C Crônica/virologia
Quimioterapia Combinada
Simeprevir/efeitos adversos
Sofosbuvir/efeitos adversos
Resposta Viral Sustentada
Genótipo
Limites: Humanos
Responsável: BR1.1 - BIREME


  4 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Alvares-da-Silva, Mario Reis
Texto completo
Id: biblio-1115980
Autor: Costa, Marisa Boff; Longo, Larisse; Santos, Deivid; Costa, Raquel Boff da; Dellavia, Gustavo Hirata; Arruda, Soraia; Michalczuk, Matheus Truccolo; Álvares-da-Silva, Mário Reis.
Título: Clinical and epidemiological profile of HCV genotype 3 patients in southern Brazil
Fonte: Clin. biomed. res;40(1):7-13, 2020.
Idioma: en.
Resumo: Introduction: Despite the emergence of new treatments for HCV genotype 3 (HCV G3), there is still a lack of data about this particular subgroup in Brazil. Our objective was to describe clinical and sociodemographic variables and treatment profile of HCV G3 Brazilian patients. Methods: This was a descriptive, retrospective study, performed in a specialized center for HCV treatment in the South Region of Brazil. Medical records of patients diagnosed with HCV G3 were reviewed to collect clinical, sociodemographic, and treatment information. Results: Participants included total of 564 patients, with a mean age of 59.3 years (SD = 10.5). Cirrhosis was present in 54.4% of patients. The most common coexisting conditions were systemic arterial hypertension (36.6%) and diabetes mellitus (30%). Regarding treatment, 25.2% of the patients were treatment-naïve and 74.8% were currently under treatment (11.6%) or had received a previous treatment (87%). The most frequent ongoing treatment was sofosbuvir + daclatasvir (± ribavirin) (87.8%). Of the 388 patients who had at least one previous treatment, 67% achieved sustained virologic response in the last treatment. Caucasian / white, non-obese, transplanted patients, those with longer time since diagnosis and with cirrhosis were more likely to receive treatment, according to multivariate analysis. Patients with hepatocellular carcinoma were 64.1% less likely to be on treatment during the study period than those without this condition; patients with chronic kidney disease were 2.91-fold more likely to have an interruption of treatment than those without this condition. Conclusion: This study describes a large sample of Brazilian patients with HCV G3. Treatment patterns were mainly influenced by the presence of HCV complications and comorbidities.(AU)
Descritores: Hepatite C/virologia
Hepacivirus/genética
Genótipo
-Antivirais/uso terapêutico
Ribavirina/uso terapêutico
Estudos Retrospectivos
Interferons/uso terapêutico
Hepatite C/tratamento farmacológico
Hepatite C/epidemiologia
Carcinoma Hepatocelular/tratamento farmacológico
Suspensão de Tratamento
Sofosbuvir/uso terapêutico
Cirrose Hepática/tratamento farmacológico
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Responsável: BR18.1 - Biblioteca FAMED/HCPA


  5 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974205
Autor: Ferreira, Vinicius Lins; Borba, Helena Hiemisch Lobo; Wiens, Astrid; Pedroso, Maria Lucia Alves; Radunz, Vanessa Ferreira de Camargo; Ivantes, Cláudia Alexandra Pontes; Kuniyoshi, Aline Satie Oba; Pontarolo, Roberto.
Título: Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
Fonte: Braz. j. infect. dis;22(3):186-192, May-June 2018. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background This study aimed to evaluate the clinical effectiveness in terms of sustained virological response and tolerability of available second generation direct-acting antivirals in Brazilian patients. Methods This was a retrospective observational study conducted in six centers in Southern Brazil. The sample comprised adult patients who were chronically infected with hepatitis C virus, regardless of virus genotype, fibrosis stage, or prior treatment. Statistical analysis was performed to compare the effectiveness among the treatments, and also to uncover the factors influencing the achievement of sustained virological response. Results A total of 296 patients were included in the study, with the majority receiving sofosbuvir with daclatasvir (59%) or sofosbuvir with simeprevir (26%). Overall sustained virological response rates were approximately 91.6%. For genotype 1, sofosbuvir with daclatasvir had an sustained virological response rate of approximately 95%, while the sustained virological response rate of sofosbuvir with simeprevir was 92%; this difference was statistically significant only for subtype 1b. The only treatment used for genotype 3 patients was sofosbuvir with daclatasvir, and lower rates of sustained virological response were observed for this group, compared to genotype 1 (84% versus 95%, p < 0.05). Apart from this difference between genotypes, and a difference between patients who achieved rapid virologic response compared with those who did not, there were no other statistically significant factors associated with sustained virological response. Conclusions The results point to the effectiveness of second-generation direct-acting antivirals in hepatitis C virus Brazilian patients, especially those with genotype 1. Furthermore, that patients with genotype 3 need more attention and adjustments in available treatment options.
Descritores: Antivirais/farmacologia
Hepatite C Crônica/tratamento farmacológico
-Valores de Referência
Ribavirina/farmacologia
Fatores de Tempo
Brasil
Modelos Logísticos
Reação em Cadeia da Polimerase
Estudos Retrospectivos
Carga Viral
Hepatite C Crônica/complicações
Relação Dose-Resposta a Droga
Simeprevir/farmacologia
Sofosbuvir/farmacologia
Resposta Viral Sustentada
Imidazóis/farmacologia
Cirrose Hepática/virologia
Limites: Humanos
Masculino
Feminino
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  6 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-974227
Autor: Holzmann, Iandra; Tovo, Cristiane V; Minmé, Roseline; Leal, Mônica P; Kliemann, Michele P; Ubirajara, Camila; Aquino, Amanda A; Araujo, Bruna; Almeida, Paulo R L.
Título: Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
Fonte: Braz. j. infect. dis;22(4):317-322, July-Aug. 2018. tab.
Idioma: en.
Resumo: ABSTRACT Introduction Chronic hepatitis C virus infection is one of the major causes of cirrhosis, hepatocellular carcinoma and liver transplantation. Treatment using direct-acting antivirals has revolutionized the treatment of hepatitis C virus, increasing long-term prognosis after cure. The goal of the present study was to evaluate the effectiveness of direct-acting antivirals in a Public Health System in southern Brazil. Methods A retrospective study evaluated all patients with chronic hepatitis C virus infection who underwent treatment at one center of the Public Health Department of the State of Rio Grande do Sul - Brazil, according to the Brazilian Clinical Protocol and Therapeutic Guidelines. The effectiveness was assessed in terms sustained virological response 12 weeks after the end of treatment. Results A total of 1002 patients who were treated for chronic hepatitis C virus infection were evaluated. The mean age was 58.6 years, 557 patients (55.6%) were male and 550 (54.9%) were cirrhotic. Overall sustained virological response was observed in 936 (93.4%) patients. There was a difference in sustained virological response rate varied according to sex, 91.6% in men and 95.7% in women (p= 0.009), length of treatment in genotype 1, 92.7% with 12 weeks and 99.1 with 24 weeks (p= 0.040), and genotype, 94.7% in genotype 1, 91.7% in genotype 2, and 91.4% in genotype 3 (p= 0.047). Conclusion The treatment of chronic hepatitis C virus infection for genotypes 1, 2 or 3 with the therapeutic regimens established by the Brazilian guidelines showed high rates of SVR, even in cirrhotic patients.
Descritores: Antivirais/uso terapêutico
Saúde Pública/estatística & dados numéricos
Hepatite C Crônica/tratamento farmacológico
Resposta Viral Sustentada
-Ribavirina/uso terapêutico
Brasil
Estudos Retrospectivos
Guias de Prática Clínica como Assunto
Hepacivirus/genética
Carga Viral
Hepatite C Crônica/genética
Quimioterapia Combinada
Simeprevir/uso terapêutico
Sofosbuvir/uso terapêutico
Genótipo
Imidazóis/uso terapêutico
Cirrose Hepática
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  7 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1089328
Autor: Rossato, Giovana; Tovo, Cristiane Valle; Almeida, Paulo Roberto Lerias de.
Título: Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes
Fonte: Braz. j. infect. dis;24(1):25-29, Feb. 2020. tab, graf.
Idioma: en.
Resumo: ABSTRACT Background: To analyze the effectiveness and the safety of Sofosbuvir-based regimens to treat patients with chronic hepatitis C virus (HCV) infection and chronic kidney disease (CKD). Methods: A retrospective, observational study in patients with chronic HCV infection and CKD treated with Sofosbuvir-based regimens was performed. Liver fibrosis, comorbidities, HCV genotype and sustained virological resposnse (SVR) at 12th week post-treatment were evaluated. Kidney function was accessed by serum creatinine and glomerular filtration rate (GFR). The assumed level of significance was 5 %. Results: Thirty-five patients were treated. The mean age was 52.1 ± 10.9 years, 19 (54.3 %) were women, 32 (91.4 %) were already kidney transplanted and 3 (8.6 %) were on hemodialysis. The SVR by intention to treat was 88.6 %. The mean GFR was 65.8 ± 28.6 and 63.7 ± 28.3 ml/min pre- and post-treatment respectively (p > 0.05). Treatment was interrupted in 1 (2.85 %) patient due to anemia and in 2 (5.7 %) due to loss of kidney function. Conclusion: Sofosbuvir-based regimens are effective to treat HCV in patients with CKD. In patients with mild CKD this type of therapy seems to be safe.
Descritores: Antivirais/uso terapêutico
Hepatite C Crônica/tratamento farmacológico
Insuficiência Renal Crônica/fisiopatologia
Sofosbuvir/uso terapêutico
-Índice de Gravidade de Doença
Reprodutibilidade dos Testes
Estudos Retrospectivos
Análise de Variância
Transplante de Rim
Resultado do Tratamento
Estatísticas não Paramétricas
Creatinina/sangue
Insuficiência Renal Crônica/terapia
Resposta Viral Sustentada
Taxa de Filtração Glomerular
Imidazóis/uso terapêutico
Imunossupressores/uso terapêutico
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Tipo de Publ: Estudo Observacional
Responsável: BR1.1 - BIREME


  8 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1099466
Autor: Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde.
Título: Informe diário de evidências COVID-19: busca realizada em 29 de maio de 2020 / COVID-19 daily evidence report: search conducted on May 29, 2020.
Fonte: s.l; s.n; 29 maio 2020.
Idioma: pt.
Resumo: O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológica (revisões sistemáticas, ensaios clínicos randomizados, coortes, entre outros). Para cada estudo é apresentado um resumo com avaliação da qualidade metodológica. Essa avaliação tem por finalidade identificar o grau de certeza/confiança ou o risco de viés de cada estudo. Para tal, são utilizadas ferramentas já validadas e consagradas na literatura científica, na área de saúde baseada em evidências. Cabe ressaltar que o documento tem caráter informativo e não representa uma recomendação oficial do Ministério da Saúde sobre a temática. Foram encontrados 13 artigos e 13 protocolos.
Descritores: Pneumonia Viral/tratamento farmacológico
Infecções por Coronavirus/tratamento farmacológico
Betacoronavirus/efeitos dos fármacos
-Sistema Renina-Angiotensina
Avaliação da Tecnologia Biomédica
Zinco/uso terapêutico
Ivermectina/uso terapêutico
Cloroquina/uso terapêutico
Anti-Inflamatórios não Esteroides/uso terapêutico
Azitromicina/uso terapêutico
Ritonavir/uso terapêutico
Oseltamivir/uso terapêutico
Inibidores da Dipeptidil Peptidase IV/uso terapêutico
Geleia de Wharton
Lopinavir/uso terapêutico
Sulfato de Atazanavir/uso terapêutico
Sofosbuvir/uso terapêutico
Interferon alfa-2/uso terapêutico
Hidroxicloroquina/uso terapêutico
Limites: Humanos
Tipo de Publ: Relatos de Casos
Revisão
Estudo de Avaliação
Responsável: BR1.1 - BIREME


  9 / 18 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1104209
Autor: Centro Nacional de Excelencia Tecnológica en Salud.
Título: Perspectivas de tratamiento para COVID-19 (en progreso) / Treatment prospects for COVID-19 (in progress).
Fonte: Ciudad de México; CENETEC; 19 jun. 2020.
Idioma: es.
Resumo: CONTEXTO: Debido a la contingencia por COVID-19 provocada por el nuevo coronavirus, SARS-CoV-2, en la actualidad hay una intensa investigación de alternativas terapéuticas que sean seguras y eficaces. (Hay registrados 2208 protocolos de estudios en ClinicalTrials.gov1). Con el propósito de conocer el panorama terapéutico actual contra COVID-19, se realizó una búsqueda exhaustiva de las alternativas que han demostrado cierta eficacia en esta infección, concluyendo que los estudios que se han realizado tienen limitaciones metodológicas. Se trata de estudios no controlados, con alta probabilidad de sesgos que comprometen la validez interna y externa, consideran evidencia indirecta o la experiencia de expertos ante esa emergencia sanitaria, por lo que toda recomendación derivada de estos documentos debe de tomarse con extrema cautela. El uso de esas alternativas debe considerar los riesgos y los beneficios en casos individuales, en una decisión compartida entre médicos, pacientes y familiares ya que la mayoría de la evidencia se considera de baja o muy baja calidad. A la fecha no existe tratamiento específico en contra de este virus. BÚSQUEDA REALIZADA: Inmunoglobulinas intravenosas: Las inmunoglobulinas intravenosas (IgIV) es un grupo de IgG obtenido de donantes sanos, expuestos a enfermedades infecciosas endémicas, vacunas y microorganismos ubicuos que participan en la producción de anticuerpos IgG contra diferentes microorganismos y sus productos. El uso de inmunoglobulina intravenosa se ha
Descritores: Pneumonia Viral/tratamento farmacológico
Ribavirina/uso terapêutico
Timosina/uso terapêutico
Ivermectina/uso terapêutico
Dexametasona/uso terapêutico
Cloroquina/uso terapêutico
Imunoglobulinas Intravenosas/uso terapêutico
Infecções por Coronavirus/tratamento farmacológico
Ritonavir/uso terapêutico
Lopinavir/uso terapêutico
Darunavir/uso terapêutico
Cobicistat/uso terapêutico
Sofosbuvir/uso terapêutico
Hidroxicloroquina/uso terapêutico
-Avaliação da Tecnologia Biomédica
Avaliação em Saúde
Limites: Humanos
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  10 / 18 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-991422
Autor: Bellido-Caparó, Álvaro; Rosado, Mavel; Espinoza-Ríos, Jorge; Tagle Arróspide, Martin.
Título: Tratamiento exitoso con los nuevos antivirales de acción directa en paciente infectado con el virus de la hepatitis C con fibrosis avanzada y dos recaídas previas: Reporte de caso / Successful treatment with new direct acting antiviral in an infected patient with hepatitis C virus with advanced liver fibrosis in a treatment experienced patient: Case report
Fonte: Rev. méd. hered;28(3):187-191, jul.-set. 2017. tab.
Idioma: es.
Resumo: El tratamiento del virus de la hepatitis C ha presentado grandes cambios en los últimos años. El esquema base utilizado era Interferón Pegylado y Ribavirina, con el que se lograba respuesta viral sostenida (RVS) de alrededor del 50%. Con la adición de los inhibidores de proteasa Telaprevir y Boceprevir al esquema "esqueleto" de Interferon Pegylado y Ribavirina, la tasa de RVS mejoró hasta valores cercanos a 70%; sin embargo, ocurren efectos colaterales importantes y difícil adherencia. Los nuevos antivirales de acción directa (AAD) (inhibidores de la polimerasa NS5A y NS5B), tienen altas tasas de RVS alcanzando valores mayores de 95% en los diferentes genotipos, en pacientes que recibieron tratamiento previo o no, incluyendo cirróticos. Se presenta el caso de un paciente que recibió dos esquemas terapéuticos previos y con fibrosis hepática avanzada que presentó RVS al ser tratado con los nuevos AAD (Sofosbuvir y Ledipasvir). (AU)

The treatment of hepatitis C virus utilized was Pegylated Interferon and Ribavirin, achieving a sustained virological response (SVR) of about 50 %. With the addition of the first-generation protease inhibitors Telaprevir and Boceprevir to the Pegylated Interferon/Ribavirin backbone the SVR rates rose up to approximately 70%, but with important side effects and a difficult adherence. The new direct acting antivirals (NS5A and NS5B polymerase inhibitors) improved SVR rates to 95 % or greater in the different genotypes, in the treatment-naive and treatment experienced patients including patients with cirrhosis. We report the case of a patient with advanced fibrotic stage, who failed to respond to 2 regimens and was subsequently treated with Ledipasvir/Sofosbuvir and achieved virogical cure. (AU)
Descritores: Interferons
Hepatite C/terapia
Hepacivirus
Sofosbuvir/uso terapêutico
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: PE1.1 - Oficina Universitária de Biblioteca



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde